Oncopeptides AB (ONCO) - Total Liabilities
Based on the latest financial reports, Oncopeptides AB (ONCO) has total liabilities worth Skr193.73 Million SEK (≈ $20.85 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oncopeptides AB - Total Liabilities Trend (2014–2025)
This chart illustrates how Oncopeptides AB's total liabilities have evolved over time, based on quarterly financial data. See ONCO current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Oncopeptides AB Competitors by Total Liabilities
The table below lists competitors of Oncopeptides AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AIFORIA TECHNOLOGIES OYJ
F:L6J
|
Germany | €12.11 Million |
|
Doosan Fuel Cell Co. Ltd. Pfd. Series 1
KO:33626K
|
Korea | ₩830.94 Billion |
|
BQE Water Inc
V:BQE
|
Canada | CA$6.91 Million |
|
Nusa Raya Cipta Tbk
JK:NRCA
|
Indonesia | Rp1.41 Trillion |
|
Abra Information Technologies Ltd
TA:BBYL
|
Israel | ILA23.47 Million |
|
Aureus Greenway Holdings Inc. Common Stock
NASDAQ:AGH
|
USA | $2.04 Million |
|
Argosy Minerals Ltd
AU:AGY
|
Australia | AU$275.46K |
Liability Composition Analysis (2014–2025)
This chart breaks down Oncopeptides AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Oncopeptides AB worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncopeptides AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncopeptides AB (2014–2025)
The table below shows the annual total liabilities of Oncopeptides AB from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr193.73 Million ≈ $20.85 Million |
+2.01% |
| 2024-12-31 | Skr189.91 Million ≈ $20.44 Million |
+4.58% |
| 2023-12-31 | Skr181.60 Million ≈ $19.54 Million |
+99.49% |
| 2022-12-31 | Skr91.03 Million ≈ $9.80 Million |
-60.16% |
| 2021-12-31 | Skr228.51 Million ≈ $24.59 Million |
-38.22% |
| 2020-12-31 | Skr369.86 Million ≈ $39.80 Million |
+88.25% |
| 2019-12-31 | Skr196.47 Million ≈ $21.14 Million |
+52.66% |
| 2018-12-31 | Skr128.70 Million ≈ $13.85 Million |
+108.19% |
| 2017-12-31 | Skr61.82 Million ≈ $6.65 Million |
+111.01% |
| 2016-12-31 | Skr29.30 Million ≈ $3.15 Million |
+318.39% |
| 2015-12-31 | Skr7.00 Million ≈ $753.53K |
+26.91% |
| 2014-12-31 | Skr5.52 Million ≈ $593.73K |
-- |
About Oncopeptides AB
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company's PDC platform desig… Read more